Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: D.Right who wrote (943)	11/12/1997 6:42:00 PM
From: D.Right	Read Replies (1) \| Respond to of 2173

Damage Assessment How bad is today's news? It is pretty bad. To be exact, it is about 12 to 18 months bad. The stock price may have more down-side risks from here because of the news. Well, from the point of view of how bad it is for the company value, it may not be as bad as the stock price may get in coming days. It looks like the company is quite confident about the prospect of pramlintide in type II populaion. It is risking a big hit from Wall Street for delayed launch of pramlintide in type I population to try to get the tpye II number coming along. It must have been a tough call to make. Another bad news coming with the news is that AMLN has to get more money because of this delay to finish the trials. I believe they have to wait until they get the European trial numbers. Only after some good numbers from European trials they can even think about stock offering. All that said, if this increases the chance of getting both type I and II population approval, the final profit goal may get better. Just one and half years more though. Take it easy everybody and DON'T CHECK AMLLN'S PRICE FOR THE NEXT THREE MONTHS. D.Right